BBIO - BridgeBio Pharma Inc

-

$undefined

N/A

(N/A)

BridgeBio Pharma Inc NASDAQ:BBIO BridgeBio Pharma Inc. is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio's pipeline of over 20 development programs includes product candidates ranging from early discovery to late-stage development.

Location: 421 Kipling St, California, 94301-1530, US | Website: bridgebio.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

6.704B

Cash

266.3M

Avg Qtr Burn

-112.6M

Short % of Float

13.26%

Insider Ownership

5.40%

Institutional Own.

94.16%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Attruby™ (Acoramidis) (AG10) Details
Transthyretin Amyloid Cardiomyopathy

Approved

Quarterly sales

NULIBRY (Fosdenopterin) (BBP-870/ORGN001) Details
Molybdenum cofactor deficiency type A

Approved

Quarterly sales

Infigratinib Details
Achondroplasia

Phase 3

Data readout

BBP-418 Details
Limb-Girdle Muscular Dystrophy

Phase 3

Data readout

Encaleret Details
Autosomal Dominant Hypocalcemia Type 1

Big Mover™

Susp. Mover™

Phase 3

Data readout

Infigratinib Details
Hypochondroplasia

Phase 2

Data readout

BBP-398 + OPDIVO Details
Solid tumor/s, Lung cancer, Non-small cell lung carcinoma

Phase 1/2

Data readout

BBP- 812 Details
Canavan disease

Phase 1/2

Update

BBO-8520 (KRASG12C inhibitor) Details
Non-small cell lung carcinoma, Lung cancer, Solid tumor/s

Phase 1

Data readout

BBO-10203 Details
Hyperglycemia

IND

Submission

Failed

Discontinued

BBP-631 Details
Congenital adrenal hyperplasia

Failed

Discontinued